These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 12171897

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon alpha combined with paclitaxel.
    Tedjarati S, Baker CH, Apte S, Huang S, Wolf JK, Killion JJ, Fidler IJ.
    Clin Cancer Res; 2002 Jul; 8(7):2413-22. PubMed ID: 12114447
    [Abstract] [Full Text] [Related]

  • 25. Anoikis induction by quinazoline based alpha 1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2.
    Keledjian K, Kyprianou N.
    J Urol; 2003 Mar; 169(3):1150-6. PubMed ID: 12576871
    [Abstract] [Full Text] [Related]

  • 26. Paradoxical and contradictory effects of imatinib in two cell line models of hormone-refractory prostate cancer.
    Cardoso HJ, Vaz CV, Correia S, Figueira MI, Marques R, Maia CJ, Socorro S.
    Prostate; 2015 Jun 15; 75(9):923-35. PubMed ID: 25786656
    [Abstract] [Full Text] [Related]

  • 27. Antitumour activity of novel taxanes that act at the same time as cytotoxic agents and P-glycoprotein inhibitors.
    Ferlini C, Distefano M, Pignatelli F, Lin S, Riva A, Bombardelli E, Mancuso S, Ojima I, Scambia G.
    Br J Cancer; 2000 Dec 15; 83(12):1762-8. PubMed ID: 11104578
    [Abstract] [Full Text] [Related]

  • 28. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
    Joseph IB, Isaacs JT.
    Cancer Res; 1997 Mar 15; 57(6):1054-7. PubMed ID: 9067270
    [Abstract] [Full Text] [Related]

  • 29. Cellular bases of the antitumor activity of a 7-substituted camptothecin in hormone-refractory human prostate carcinoma models.
    Zuco V, Supino R, De Cesare M, Carenini N, Perego P, Gatti L, Pratesi G, Pisano C, Martinelli R, Bucci F, Zanier R, Carminati P, Zunino F.
    Biochem Pharmacol; 2003 Apr 15; 65(8):1281-94. PubMed ID: 12694869
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.
    Bianco R, Caputo R, Caputo R, Damiano V, De Placido S, Ficorella C, Agrawal S, Bianco AR, Ciardiello F, Tortora G.
    Clin Cancer Res; 2004 Jul 15; 10(14):4858-64. PubMed ID: 15269162
    [Abstract] [Full Text] [Related]

  • 33. Histone deacetylase inhibitor potentiates anticancer effect of docetaxel via modulation of Bcl-2 family proteins and tubulin in hormone refractory prostate cancer cells.
    Hwang JJ, Kim YS, Kim MJ, Kim DE, Jeong IG, Kim CS.
    J Urol; 2010 Dec 15; 184(6):2557-64. PubMed ID: 21030039
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. MJ-29 inhibits tubulin polymerization, induces mitotic arrest, and triggers apoptosis via cyclin-dependent kinase 1-mediated Bcl-2 phosphorylation in human leukemia U937 cells.
    Yang JS, Hour MJ, Huang WW, Lin KL, Kuo SC, Chung JG.
    J Pharmacol Exp Ther; 2010 Aug 15; 334(2):477-88. PubMed ID: 20463006
    [Abstract] [Full Text] [Related]

  • 36. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.
    Cancer Res; 2003 Sep 15; 63(18):5978-91. PubMed ID: 14522925
    [Abstract] [Full Text] [Related]

  • 37. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity.
    Giannakakou P, Robey R, Fojo T, Blagosklonny MV.
    Oncogene; 2001 Jun 28; 20(29):3806-13. PubMed ID: 11439344
    [Abstract] [Full Text] [Related]

  • 38. In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines.
    Avramis IA, Christodoulopoulos G, Suzuki A, Laug WE, Gonzalez-Gomez I, McNamara G, Sausville EA, Avramis VI.
    Cancer Chemother Pharmacol; 2002 Dec 28; 50(6):479-89. PubMed ID: 12451475
    [Abstract] [Full Text] [Related]

  • 39. Anti-tumour activity of a panel of taxanes toward a cellular model of human cervical cancer.
    Gallo D, Ferlini C, Distefano M, Cantelmo F, Gaggini C, Fattorossi A, Riva A, Bombardelli E, Proietti E, Mancuso S, Scambia G.
    Cancer Chemother Pharmacol; 2000 Dec 28; 45(2):127-32. PubMed ID: 10663627
    [Abstract] [Full Text] [Related]

  • 40. Antitumor activity and downregulation of pro-angiogenic molecules in human prostate cancer cells by a novel thiazolidione compound.
    Teraishi F, Wu S, Inoue S, Zhang L, Davis JJ, Guo W, Dong F, Fang B.
    Prostate; 2006 Mar 01; 66(4):430-8. PubMed ID: 16302260
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.